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OBJECTIVE
To evaluate effects of the dual sodium–glucose cotransporter (SGLT) 1 and SGLT2
inhibitor sotagliflozin in combinationwith insulin on glucose time in range (TIR) and
glucoseexcursions, postprandial glucose (PPG), andother glycemicmetrics in adults
with type 1 diabetes using masked continuous glucose monitoring (CGM).
RESEARCH DESIGN AND METHODS
Data sets from the inTandem1 (clinical trial reg. no. NCT02384941) and inTandem2
(clinical trial reg. no. NCT02421510) double-blind randomized trials evaluating
sotagliflozin versus placebo in adults with type 1 diabetes treated with optimized
insulin were pooled for analyses of masked CGMdata from a subset of participants
in each trial. The pooled cohort included patients randomized to receive placebo (n =
93), sotagliflozin 200 mg (n = 89), or sotagliflozin 400 mg (n = 96). The primary
outcomewas change frombaseline toweek24 in glucose TIR (3.9–10.0mmol/L [70–
180mg/dL]). Secondary end points included time belowand above the target range
and 2-h PPG level assessed after a standardized mixed meal.
RESULTS
MeanpercentageofglucoseTIR/percentage timespentat<3.9mmol/L (<70mg/dL)
during week 24 was 51.6%/5.9%, 57.8%/5.5%, and 64.2%/5.5% with placebo,
sotagliflozin 200mg, and sotagliflozin 400mg, respectively, which corresponded to
a placebo-adjusted change from a baseline of +5.4%/20.3% (P = 0.026; +1.3/20.1
h/day) for sotagliflozin 200 mg and +11.7%/20.1% (P < 0.001; +2.8/20.02 h/day)
for sotagliflozin 400 mg. Placebo-adjusted PPG reductions were 1.96 0.7 mmol/L
(35 6 13 mg/dL; P = 0.004) and 2.8 6 0.7 mmol/L (50 6 13 mg/dL; P < 0.001)
with sotagliflozin 200 and 400 mg, respectively.
CONCLUSIONS
Combined with optimized insulin in type 1 diabetes, sotagliflozin significantly
increased glucose TIR without increasing time spent at <3.9 mmol/L and reduced
PPG, thereby improving glycemic control.
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Managing type 1 diabetes is a challenge
for even skilled, experienced patients
and clinicians. Although insulin therapy
is lifesaving for patients with type 1 di-
abetes, and intensive glycemic control
reduces the complications of diabetes
(1), it exposes patients to hypoglycemia
and weight gain. Moreover, many pa-
tients have difficulty controlling glucose
fluctuations,whichcanoccuronaminute-
by-minute basis. Because HbA1c does
not reflect short-term variations in blood
glucose, daily exposure to hypoglycemia
and hyperglycemia, or the impact of
blood glucose variations on patients’
quality of life, the international Type 1
Diabetes Outcomes Program recently
recommended an additional set of
type 1 diabetes outcomes measures be-
yond HbA1c level. These include glucose
time in range (TIR), hypoglycemia, hy-
perglycemia, and the incidence of dia-
betic ketoacidosis (DKA) (2). Further
refining glycemic outcomes beyond
HbA1c, an international consensus group
recently recommended 15 key metrics
for continuous glucose monitoring
(CGM) analyses and reporting, with par-
ticular emphasis on percentage of TIR at
3.9–10.0 mmol/L (70–180 mg/dL) and a
means of alerting patients when glucose
exceeds or is below this range (3).
The challenges of managing type 1
diabetes have prompted interest in in-
sulin adjuncts, with the goal of improving
glycemic control without increasing hy-
poglycemia or weight gain (4,5). To date,
onlypramlintidehasbeenapprovedasan
adjunct to insulin for the treatment of
type 1 diabetes, but this agent requires
prandial injections and is associated with
an increased risk of severehypoglycemia,
nausea, and vomiting (4,6). Studies of
incretin mimetics (i.e., dipeptidyl pepti-
dase 4 inhibitors and glucagon-like pep-
tide 1 receptor agonists) and metformin
have shown few if any benefits (7–10),
but sodium–glucose cotransporter (SGLT)
inhibitors have shown promise in combi-
nation with insulin for type 1 diabetes
management (11–16).
Sotagliflozin (LX4211) is a novel dual
inhibitor of SGLT1 and SGLT2 that de-
creases renal glucose reabsorption
through systemic SGLT2 inhibition. In
addition, SGLT1 inhibition reduces glu-
cose absorption in the proximal gastro-
intestinal tract, causing a blunting and
delay of postprandial glucose (PPG)
(17–19). The resulting lower peak PPG
should reduce time above the goal blood
glucose range and increase the time
within that range (i.e., TIR), resulting in
less glycemic variability. The inTandem
phase3programconsistsofthreecompleted
international, randomized, double-blind,
placebo-controlled trials of sotagliflozin
combined with insulin for the treat-
ment of type 1 diabetes (11–13). In
each, sotagliflozin significantly reduced
HbA1c, fasting plasma glucose, body
weight, and blood pressure (in patients
with SBP $130 mmHg) and increased
the proportion of patients achieving
HbA1c ,7.0% and those achieving com-
posite outcomes consisting of HbA1c
,7.0% without severe hypoglycemia or
DKA or HbA1c reductions $0.5% without
severe hypoglycemia or DKA.
The inTandem1 and inTandem2 trials
had identical trial designs inwhich insulin
therapy was optimized for all patients
starting 6 weeks before the initiation of
oral therapy to identify incremental ef-
fects of sotagliflozin that could not be
achieved by merely increasing insulin
doses (12,13). These trials included a
randomly selected subgroup of patients
who underwent masked CGM to assess
the effect of sotagliflozin on TIR and
glycemic variability as well as the assess-
ment of 2-h PPG to evaluate postmeal
glucose excursions. Here, we describe the
results of pooled analyses of data from
the CGM substudies from inTandem1
and inTandem2.
RESEARCH DESIGN AND METHODS
Design Overview
Prespecified pooled analyses were con-
ducted using 24-week CGM substudy
data from two phase 3, 52-week, multi-
center, randomized, double-blind, placebo-
controlled, parallel-group trials of oral
sotagliflozin 200 or 400 mg once daily
in combination with optimized insulin
in adults with type 1 diabetes who
had inadequate glycemic control on
insulin alone. The trials were conducted
in the U.S. and Canada (inTandem1
[clinical trial reg. no. NCT02384941,
ClinicalTrials.gov]) and Europe and Is-
rael (inTandem2 [clinical trial reg. no.
NCT02421510, ClinicalTrials.gov]); trial
design details have been previously re-
ported (12,13).
Participants in the CGM substudy of
each trial underwent masked CGM with
a Dexcom G4monitor (Dexcom, Inc., San
Diego, CA) during specified 1-week
intervals throughout the first 24 weeks:
week 21 to baseline, week 3–4, week
11–12, and week 23–24. Because it was
possible that the CGMsubstudies of each
trial would not meet their individual
enrollment targets (n = 70/arm), the
inTandem1 and inTandem2 protocols
were modified before data were un-
masked to include prespecified pooled
analyses of CGM data. At baseline and
week 24, CGM substudy participants
had 2-h plasma PPG assessments after
ingesting a standardized mixed liquid
nutrition drink with bolus insulin matched
to the carbohydrate content of the meal
(Supplementary Data) (20,21).
The institutional review boards for
each study center or the local ethics
committees approved the protocol, con-
sent form, and associated documents. All
patients provided written informed con-
sent. An independent statistician per-
formed statistical analyses.
Study Population
The inTandem program included men
and nonpregnant women $18 years
of age who had type 1 diabetes treated
with insulin delivered via multiple daily
injections (MDI) or continuous subcuta-
neous insulin infusion (CSII) whose HbA1c
was between 7.0% and 11.0% at screen-
ing. Full details have been published
previously (12,13).
Interventions
After a 6-week insulin optimization
phase, patients were randomly assigned
in a 1:1:1 ratio to placebo, sotagliflozin
200 mg, or sotagliflozin 400 mg, given
as two tablets administered orally once
daily. Insulin optimization continued
throughout the trial for all patients. Re-
gardless of the HbA1c level achieved at
the end of the optimization period, all
patients were randomly assigned to
treatment. Study personnel adjusted
basal and bolus insulin doses to maintain
fasting or preprandial blood glucose be-
tween 4.4 and 7.2 mmol/L (80 and
130 mg/dL) and 1- to 2-h PPG
,10 mmol/L (,180 mg/dL) based on
self-monitored blood glucose (SMBG)
patterns (12,13).
End Points
The primary efficacy end point was the
change from baseline to week 24 (week
23–24 period) in percentage of TIR
of 3.9–10.0 mmol/L (70–180 mg/dL).
Secondary end points included percent-
age time and area under the curve (AUC)
outside the target range. These corre-
spond to hyperglycemia (.10.0 mmol/L
[.180 mg/dL]), hypoglycemia (,3.9
mmol/L [,70 mg/dL]), and the change
from baseline to week 24 in AUC values
above or below different thresholds
(.10.0 or .13.9 mmol/L [.180 or
.250 mg/dL]; ,3.0 or ,3.9 mmol/L
[,55 or ,70 mg/dL]) by time of day
(full 24-h day, diurnal period [0600 to
2359 h], nocturnal period [0000 to
0559 h]) and the change from baseline
in 2-h PPG (measured as plasma glucose)
after a standardized mixed meal at week
24. To provide context on the risk of
hypoglycemia, CGM TIR is expressed
similarly to blood pressure, as percent-
age of TIR (3.9–10.0 mmol/L [70–180
mg/dL])/percentage time ,3.9 mmol/L
(,70 mg/dL). Glycemic variability was
assessed with CGM data including the
SD of glucose, mean daily glucose,
mean amplitude of glycemic excursions
(MAGE), and coefficient of variation (CV)
as previously defined (22,23). Hypogly-
cemia by CGM was defined as at least
10 min of continuous CGM readings
below the thresholds of 3.9 mmol/L
(70 mg/dL) or 3.0 mmol/L (55 mg/dL).
Statistical Methods
Analyses of CGM data were based on the
modified intent-to-treat subpopulation
participating in the CGM substudy of
each trial, which included all randomized
CGMpatients who had taken at least one
dose of study drug. Three to 7 daysworth
of valid CGM recordings were required
for a visit to be used for analysis; a visit
consisted of a weekly session of record-
ings. For any day within a visit to be
eligible,$80% of the data points had to
have been nonmissing. Gaps in the CGM
recording for those days included in a
visit were imputed using a linear inter-
polation approach (24) of the planned
7 days. Because mealtime bolus insulin
administration directly influences PPG,
and to perform analyses under ideal
design conditions to best evaluate any
effects related to study treatment, the
PPG analyses were based on the per-
protocol population, which included all
modified intent-to-treat patients who
completed 24 weeks of treatment with-
out significant protocol deviations, took
bolus insulin and the study drug at the
designated time at the standardized
mixed meal, and completed all required
mixed meal test procedures.
Continuous, longitudinal end point
data were analyzed using the mixed-
effects model for repeated measures
method based on the restricted maxi-
mum likelihood method for estimation
with several prespecified fixed effects,
including first-order interactions with
time, and the corresponding end point
as the dependent variable in the model.
ANCOVA was used for analyses of mea-
sures taken at a single time point post-
baseline. For binary end points, the
Cochran-Mantel-Haenszel test, stratified
by the randomization stratification fac-
tors, was used. The treatment group
comparisons were performed at week
24. Missing observations at week 24 were
imputed as nonresponse in the Cochran-
Mantel-Haenszel analysis.
RESULTS
The pooled cohort included 278 adults
(136 from inTandem1 and 142 from
inTandem2) randomly assigned to re-
ceive placebo (n = 93), sotagliflozin
200 mg (n = 89), or sotagliflozin 400 mg
(n = 96). Baseline characteristics were
similar between groups (Table 1). In the
total pooled analysis, 143 (51.4%) pa-
tients used MDI and 135 (48.6%) used
CSII (Table 1).
Of the pooled cohort, sufficiently com-
plete CGM data for analyses were avail-
able for 61 of 93 patients (66%) receiving
placebo; 63 of 89 patients (71%) receiv-
ing sotagliflozin 200 mg; and 72 of 96
patients (75%) receiving sotagliflozin
400 mg. The mean percentage of TIR/
percentage time spent ,3.9 mmol/L
(,70 mg/dL) during week 24 was
51.6%/5.9%, 57.8%/5.5%, and 64.2%/
5.5% with placebo, sotagliflozin 200 mg,
and sotagliflozin 400 mg, respec-
tively. Placebo-adjusted differences from
baseline to week 24 in percentage of TIR
were 5.4%6 2.4% (95% CI 0.6–10.1; P =
0.026) and 11.7% 6 2.3% (95% CI
7.1–16.3; P , 0.001) with sotagliflozin
200 and 400 mg, respectively (Table
2), which was estimated to be an addi-
tional TIR of 1.3 h/day with sotagliflozin
200 mg and 2.8 h/day with sotagliflozin
400 mg (Fig. 1). Placebo-subtracted
changes from baseline to week 24 in the
percentage time spent .10.0 mmol/L
(.180 mg/dL) were 25.0% 6 2.6%
(95% CI 210.2 to 0.1; P = 0.055)
and 211.8% 6 2.5% (95% CI 216.7
to 26.8; P , 0.001) in the sotagliflozin
200 and 400 mg groups, translating
to 21.2 h/day and 22.8 h/day, respec-
tively. Patients receiving sotagliflozin
200 and 400 mg spent less time at
.13.9 mmol/L (.250 mg/dL) relative
to placebo; differences were 23.7% 6
1.8% (95% CI 27.3 to 20.1; P = 0.045)
and 27.7% 6 1.8% (95% CI 211.2
to24.2; P, 0.001), or 0.9 and 1.9 fewer
hours, respectively. No significant differ-
enceswere observed in the percentage of
time spent at ,3.9 mmol/L (,70 mg/dL)
or,3.0 mmol/L (,55 mg/dL) for either
dose level of sotagliflozin compared with
placebo (Table 2). Average week 24 am-
bulatory glucose profiles for each study
group are shown in Supplementary Fig. 1.
TheAUC.10.0mmol/L (.180mg/dL)
decreased significantly in both sotagli-
flozin groups by 0.56 0.2mmol/L (8.46
4.2 mg/dL) 3 minutes/1,000 (95%
CI 20.9 to 20.01; P = 0.045) with
200 mg and 1.0 6 0.2 mmol/L
(17.7 6 4.1 mg/dL) 3 minutes/1,000
(95% CI 21.4 to 20.5; P , 0.001)
with 400 mg relative to placebo (Table
2), a finding supported by CGM tracings
of mean 24-h glucose excursions (Fig. 2).
Severe hyperglycemia as measured by
AUC .13.9 mmol/L (.250 mg/dL) de-
creased by 0.4 6 0.1 mmol/L (6.9 6
2.1 mg/dL) 3 minutes/1,000 (95% CI
20.6 to 20.2; P = 0.001) with sotagli-
flozin 400 mg but was not significantly
different with sotagliflozin 200mg (Table
2). Differences from placebo for hypo-
glycemic AUC values were not statisti-
cally significant (Table 2): ,3.9 mmol/L
(,70 mg/dL), 20.006 6 0.01 mmol/L
(20.16 0.2mg/dL) for both sotagliflozin
200 and 400 mg; ,3.0 mmol/L (,55
mg/dL), 20.0006 6 0.006 mmol/L
(20.01 6 0.1 mg/dL) for sotagliflozin
200 mg and 20.002 6 0.006 mmol/L
(20.03 6 0.1 mg/dL) for sotagliflozin
400 mg. The decline in mean glucose
value from 12:00 to 6:00 A.M. in patients
treated with sotagliflozin shown in Fig. 2
was not associated with a significant
increase in nocturnal hypoglycemia.
After a standardized mixed meal
(Supplementary Data), the 2-h plasma
PPG concentration decreased by 1.9 6
0.7 mmol/L (35 6 13 mg/dL) (95%
CI23.4 to20.5; P = 0.009) with sotagli-
flozin 200 mg and by 2.8 6 0.7 mmol/L
(50 6 13 mg/dL) (95% CI 24.2 to 21.3;
P , 0.001) with sotagliflozin 400 mg
relative to placebo.
The placebo-adjusted mean daily glu-
cose concentration decreased by 0.4 6
0.3 mmol/L (7.9 6 4.7 mg/dL) (95%
CI21.0 to 0.1; P = 0.09) with sotagliflozin
200mg and by 1.16 0.3mmol/L (18.96
4.6 mg/dL) (95% CI 21.6 to 20.6; P ,
0.001)with the sotagliflozin400mgdose.
The MAGE also was reduced by 0.7 6
0.3 mmol/L (12.7 6 5.5 mg/dL) (95%
CI 21.3 to 20.1; P = 0.022) and 1.2 6
0.3 mmol/L (22.1 6 5.4 mg/dL) (95%
CI21.9 to20.7; P, 0.001) with sotagli-
flozin 200 and 400 mg, respectively,
relative to placebo. The SD for glucose
decreased in both treatment groups by
0.360.1mmol/L (4.662.3mg/dL) (95%
CI 20.5 to 20.01; P = 0.042) and 0.4 6
0.1 mmol/L (6.8 6 2.2 mg/dL) (95%
CI20.6 to20.1; P = 0.002) with sotagli-
flozin 200 and 400 mg, respectively,
relative to placebo. The CV did not differ
between the sotagliflozin and placebo
groups.
The Supplementary Data includeweek
24 CGM data for individual but repre-
sentative patients from each treatment
groupwhose baseline HbA1c values were
close to 6.5%, 7.0%, and 8.0%. At the
baseline HbA1c threshold of 6.5%
(Supplementary Fig. 2), sotagliflozin
200 and 400 mg were associated with
dose-dependent decreases in the per-
centage of time at .10.0 mmol/L
(180 mg/dL). At the higher HbA1c thresh-
olds of 7.0% (Supplementary Fig. 3) and
8.0% (Supplementary Fig. 4), patients
exhibited dose-dependent increases in
the percentage of TIR, decreases in the
percentage of time at .10.0 mmol/L,
and decreases in the percentage of time
at ,3.9 mmol/L (70 mg/dL).
Compared with placebo, hypoglyce-
mia by CGM (in number of events per
patient per day) did not differ with
sotagliflozin 200 or 400 mg at either
hypoglycemic threshold (,3.0 mmol/L
[55 mg/dL] and ,3.9 mmol/L [,70
mg/dL]) (Table 2) (all P. 0.05). Similarly,
no significant differences were ob-
served in the percentage of time spent
below hypoglycemic thresholds during
nocturnal periods or for diurnal hypo-
glycemia (Table 2).
CONCLUSIONS
In pooled analyses of masked CGM data
from two phase 3 trials involving adults
with type 1 diabetes treated with opti-
mized insulin therapy, dual inhibition
of SGLT1 and SGLT2 with sotagliflozin
significantly increased the percentage
of the TIR 3.9–10.0 mmol/L (70–180
mg/dL), reduced the percentage of time
spent at .10.0 and .13.9 mmol/L
(180 and 250 mg/dL), and reduced
PPG and glycemic variability. These find-
ings were predicted as a result of the
blunting and delay of glucose absorption
due to SGLT1 inhibition, resulting in
lower peak PPG (and less time spent
above the goal glucose range) and
more time spent in the goal glucose
range, with a net result of less glycemic
variability. These outcomes demonstrate
that sotagliflozin-produced efficacy be-
yond HbA1c was achieved without an
increase in percentage time below target
range or increased hypoglycemia risk.
With the exception of artificial pancreas
studies, this has not been observed with
insulin therapy alone (25).
High-dose (400 mg) sotagliflozin was
associated with significant improve-
ments in all CGM metrics recently rec-
ommended by an international CGM
consensus group (3) except for CV, which
was not statistically different between
treatment groups (Table 2). Changes
with high-dose sotagliflozin were consis-











inTandem1 participants, n (%) 45 (48) 44 (49) 47 (49) 136 (49)
inTandem2 participants, n (%) 48 (52) 45 (51) 49 (51) 142 (51)
Age (years) 43.5 (14.2) 44.2 (13.2) 45.1 (12.1) 44.3 (13.2)
Female sex, n (%) 52 (55.9) 47 (52.8) 48 (50.0) 147 (52.9)
Race or ethnic group, n (%)*
White 89 (95.7) 86 (96.6) 92 (95.8) 267 (96.0)
Black 2 (2.2) 0 2 (2.1) 4 (1.4)
Asian 1 (1.1) 0 0 1 (0.4)
Other 1 (1.1) 3 (3.4) 2 (2.1) 6 (2.2)
Hispanic/Latino ethnicity 5 (5.4) 4 (4.5) 7 (7.3) 16 (5.8)
HbA1c (%) 7.6 (0.7) 7.6 (0.6) 7.6 (0.7) 7.6 (0.7)
HbA1c (mmol/mol) 59.5 (7.2) 59.4 (7.0) 59.1 (8.1) 59.3 (7.4)
Diabetes duration (years) 24.6 (12.8) 22.2 (12.3) 23.4 (12.0) 23.4 (12.4)
Weight (kg) 85.5 (17.9) 86.4 (16.6) 86.1 (16.9) 86.0 (17.1)
BMI (kg/m2) 29.4 (5.5) 29.5 (4.8) 29.7 (4.9) 29.5 (5.0)
BMI $30 kg/m2, n (%) 41 (44.1) 41 (46.1) 46 (47.9) 128 (46.0)
Total daily insulin dose (IU/kg) 0.8 (0.3) 0.7 (0.2) 0.8 (0.3) 0.7 (0.3)
Daily insulin dose (IU/day)
Total 65.8 (34.6) 60.3 (24.7) 65.7 (33.0) 64.0 (31.2)
Basal 34.6 (15.9) 31.3 (14.0) 33.8 (15.0) 33.3 (15.0)
Bolus and corrections 31.2 (22.0) 28.9 (15.3) 31.9 (21.9) 30.7 (20.0)
Insulin therapy, n (%)
MDI 44 (47.3) 43 (48.3) 48 (50.0) 135 (48.6)
CSII 49 (52.7) 46 (51.7) 48 (50.0) 143 (51.4)





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































low-dose sotagliflozin (200 mg). These
observations are consistent with dose-
dependent decreases inweight andblood
pressure reported from inTandem1 and
inTandem2 (12,13). In the main studies,
the higher dose of sotagliflozin was also
associated with more DKA and mecha-
nism of action–related adverse events
including diarrhea (SGLT1 inhibition) and
genital mycotic infection (SGLT2 inhibi-
tion) (12,13). The evaluation of week
24 versus baseline CGM data for individ-
ual patients at various baseline HbA1c
thresholds further demonstrated dose-
related increases in TIR and decreases
in time spent with glucose at ,3.9
or .10.0 mmol/L, suggesting that sota-
gliflozin may provide a higher quality of
HbA1c at the HbA1c thresholds studied,
in a dose-dependent manner (26).
An international CGM consensus
group identified,3.0and.13.9mmol/L
(,54 and.250mg/dL) as action thresh-
olds for patients to avoid serious health
consequences from hypoglycemia or
hyperglycemia (the hyperglycemia ac-
tion threshold was established in patients
not treated with SGLT inhibitors) (3).
The time spent below the ,3.0 mmol/L
threshold was not increased, and the
time spent at .13.9 mmol/L significantly
decreased by nearly an hour per daywith
sotagliflozin 200 mg and nearly 2 h with
the 400 mg dose. Furthermore, a CGM
AUC .13.9 mmol/L decreased signifi-
cantly with high-dose sotagliflozin treat-
ment. Time spent at .10.0 mmol/L
(.180 mg/dL) decreased significantly
with both dose levels by more than an
hourwith the lowerdoseandbynearly3h
with the higher dose.
HbA1c is typically measured at 3-
month intervals, and SMBG profiles
are often insufficient to allow treatment
intensification without an increased risk
for hypoglycemia. The present analyses
of CGMdata during combination therapy
with sotagliflozin and insulin show how
sotagliflozin has the potential to simul-
taneously improve glycemia and reduce
the risk for hypoglycemia, thereby in-
creasing the TIR. CGMprofiles of patients
treated with sotagliflozin and placebo
with similar baseline HbA1c values
show a distinct improvement in the
amplitude of glycemic excursions. Erratic
swings of glucose levels out of the target
range have been associatedwith patient-
related outcomes such as perceived poor
health and functioning or increased anx-
iety or absenteeism (27–29). In a study
comparing basal-bolus to premixed in-
sulin therapy, improved glycemic vari-
ability was associated with improved
patient-reported outcomes (30). Like-
wise, the improvements in glycemic var-
iability shown in this studymay be related
to significant improvements in patient-
reportedoutcomesreported inthepivotal
studies of sotagliflozin (12,13).
Improvements in TIR have been re-
ported with other SGLT2 inhibitors
(14,31). These studies were performed
in patients with higher baseline mean
HbA1c and glucose values than in the
current study; therefore, improvements
in TIRmayhavebeenamplified. In a small
CGM substudy involving 89 patients with
type 1 diabetes, 18 months of canagli-
flozin treatment increased the time spent
with glucose values between 3.9 and
Figure1—Timespent inglycemic rangesof,3.9,3.9–10.0, and.10.0mmol/L (,70,70–180,and.180mg/dL)amongpatientsmonitoredwithblinded
CGM. Time values were calculated by multiplying values for the percentage of time spent in specified ranges (Table 2) by 0.24 (assumes 100% data
capture) to determine the number of hours, and the resulting right-of-decimal values by 60 to determine the number of minutes (e.g., the baseline
percentage of TIR of 3.9–10.0 mmol/L in the placebo group was 52.3% 3 0.24 = 12.552 h; 0.552 3 60 = 33 min). PBO, placebo.
10.0 mmol/L (70 and 180 mg/dL), de-
creased the time spent above and below
this range, and modestly improved gly-
cemic variability indices (31). After
24 weeks in the DEPICT-1 Trial, dapagli-
flozin significantly reduced CGM mean
glucose and MAGE and increased the
percentage of time spent within the
target range of 3.9–10.0 mmol/L (14).
The effect of canagliflozin and dapagli-
flozin on PPG in the type 1 diabetes
population has not been reported, al-
though this was a prespecified end point
of the studies (14,31).
Across the inTandem program, sota-
gliflozin treatment was associated with
significant decreases in bolus insulin
doses of 7–12% at 24 weeks (11–13).
Nevertheless, sotagliflozin significantly
reduced PPG by up to 2.8 mmol/L (50
mg/dL). A comparison of canagliflozin
and dapagliflozin suggested that SGLT1
inhibition in the proximal intestine may
confer greater PPG lowering (32). This
finding is consistent with preclinical and
clinical evidence showing that SGLT1
inhibition delays and reduces postpran-
dial hyperglycemia and also increases
the release of glucagon-like peptide
1 and polypeptide tyrosine (18,19,33).
Measures to reduce postprandial hy-
perglycemia usually increase the risk
for hypoglycemia (34,35). Sotagliflozin-
associated PPG reductions occurred
without an increase in hypoglycemia
as defined by CGM hypoglycemic events
per day, percentage of time per day, or
CGM AUC below the threshold of
3.0 mmol/L (,55 mg/dL) or 3.9 mmol/L
(,70 mg/dL). A decline in mean glu-
cose value from 12:00 to 6:00 A.M. was
observed in this substudy but was not
associated with an increased risk of
nocturnal hypoglycemia. A decrease
in mean glucose level between 12:00
and 6:00 A.M., but no increase in noc-
turnal hypoglycemia at week 24, was
also observed with dapagliflozin (36).
In the full inTandem1 and inTandem2
study populations, the incidence of docu-
mented hypoglycemia (by SMBG) and
severe hypoglycemia was numerically
lower with sotagliflozin 400 mg than
with 200 mg (12,13).
A key limitation of this study was the
masking of CGM data from investigators
and patients, whichmay have resulted in
an underrepresentation of the efficacy
of sotagliflozin in patients with type 1
diabetes who use CGM. Also, the study
requiredonly limiteduse ofmaskedCGM
at 1-week intervals. The substudy pop-
ulation also predominantly comprised
non-Hispanic whites, and the applicabil-
ity of these results to other ethnic and
racial groups is unclear.
In summary, when used in combina-
tion with optimized insulin in patients
with type 1 diabetes, sotagliflozin signif-
icantly improved multiple measures of
glycemic control beyond HbA1c. Com-
pared with placebo, sotagliflozin-treated
patients spent 1.3–2.8 h more time per
day within the range of 3.9–10.0 mmol/L
(70–180 mg/dL), with corresponding de-
creases in time spent at glucose levels
of .10.0 mmol/L (.180 mg/dL). De-
creases in PPG were accompanied by
lower mean daily glucose and reductions
in SD and the amplitude of glycemic
excursions, while there was no increase
in hypoglycemia. These data support
the use of sotagliflozin in combination
with insulin for the treatment of type 1
diabetes.
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